Clinical trials compare current state-of-the-art treatment with a potentially superior treatment and may even offer new treatment options and drugs to patients for whom there are no alternatives.
Patients at the Vall d’Hebron University Hospital’s Oncology Department are therefore considered as potential candidates for inclusion in our clinical trials . Although all patients may not be eligible or do not agree to take part in a clinical trial, we offer this option to all who meet the necessary criteria as per the different research protocols.
As a highly established reference in cancer treatment we continue to witness continued, annual growth in the number of patients starting a new treatment in clinical trials as well as number of trials conducted (see figure 1 and figure 2).
Figure 1: Annual recruitment of patients enrolled in Clinical Trials (Phases I- II - III)
|Included in phase I||35||59||57||110||130||120||108||132||139||171||222||245||277||290||345||303||370|
|Included in phase II||59||72||66||94||91||130||73||165||170||133||161||207||180||253||257||302||327|
|Included in phase III||95||128||175||109||84||129||111||85||143||180||189||221||218||236||241||166||282|
|Nº of patients included||189||259||298||313||305||379||292||382||452||484||572||673||675||779||843||771||979|
Figure 2: Annual Distribution of Phase I, II and III Trials
|Phase I trials||6||10||12||14||17||15||16||19||20||26||31||37||48||66||75||83||106|
|Phase II trials||19||22||23||23||22||19||30||32||42||40||55||54||57||85||96||99||94|
|Phase III trials||14||17||22||25||18||20||21||21||31||37||45||49||56||68||61||64||89|
|Nº of clinical trials||39||49||57||62||57||54||67||72||93||103||131||140||161||219||232||246||289|
Driving drug development & targeted therapies against cancer, the Clinical Trials Office, the Research Unit for Molecular Therapy of Cancer - "la Caixa" in collaboration with many other oncology professionals including Molecular Pathologists, Radiologists and Interventional Radiologists well as many other specialists at Vall d´Hebron (Dermatologists, Cardiologists, Ophthalmologists), along with the research carried out by the Early Clinical Drug Development Groups and other VHIO Groups, have collectively established VHIO as a leading reference in drug discovery from concept to clinic.
To find out more about our Clinical Trials Office, the Research Unit for Molecular Therapy of Cancer - "la Caixa", our Clinical Research Oncology Nurses, and Pharmacy Unit please see: